MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)

Prior treatment

• Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting)
• \< 4 cycles of chemotherapy in total
• Contraindications to endocrine therapy

Other illness

• Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol
• Any other malignancy within the last 5 years which has impact on the prognosis of the patient

Lab values

• Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption

Other

• Pregnant or lactating women
• Inability or unwillingness to swallow tablets

• Patients must be ≥ 18 years of age
• Willing and able to attend the visits and to understand all study-related procedures.
• Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer
• (Interval-) debulking performed ECOG-Performance Status 0-2
• Signed informed consents (ICF-1; ICF-2)
• Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available
• Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)
• At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)
• Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.